4683 related articles for article (PubMed ID: 29651967)
21. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
22. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
23. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
24. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
[TBL] [Abstract][Full Text] [Related]
27. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
[TBL] [Abstract][Full Text] [Related]
28. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition.
Elmeligie S; Aboul-Magd AM; Lasheen DS; Ibrahim TM; Abdelghany TM; Khojah SM; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1347-1367. PubMed ID: 31322015
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
36. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
37. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Abou-Seri SM; Eldehna WM; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 Jan; 107():165-79. PubMed ID: 26590508
[TBL] [Abstract][Full Text] [Related]
38. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
39. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives.
Xue DQ; Zhang XY; Wang CJ; Ma LY; Zhu N; He P; Shao KP; Chen PJ; Gu YF; Zhang XS; Wang CF; Ji CH; Zhang QR; Liu HM
Eur J Med Chem; 2014 Oct; 85():235-44. PubMed ID: 25086915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]